114 161

Cited 4 times in

Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study

Authors
 Gülen Hatemi  ;  Alfred Mahr  ;  Mitsuhiro Takeno  ;  Doyoung Kim  ;  Melike Melikoğlu  ;  Sue Cheng  ;  Shannon McCue  ;  Maria Paris  ;  Mindy Chen  ;  Yusuf Yazici 
Citation
 RMD OPEN, Vol.8(2) : e002235, 2022-07 
Journal Title
RMD OPEN
Issue Date
2022-07
MeSH
Behcet Syndrome* / complications ; Behcet Syndrome* / drug therapy ; Humans ; Oral Ulcer* / complications ; Oral Ulcer* / drug therapy ; Pain ; Quality of Life ; Thalidomide / analogs & derivatives
Keywords
Behcet Syndrome ; Patient Reported Outcome Measures ; Systemic vasculitis
Abstract
Objective: To assess apremilast's impact on patient quality of life (QoL) in active Behçet's syndrome and correlations between improvement in patients' QoL and efficacy measures in the phase 3 RELIEF study.

Methods: QoL measures included Behçet's Disease QoL (BDQoL), 36-Item Short-Form Health Survey V.2 (SF-36v2) Physical/Mental Component Summary (PCS/MCS) and eight subscale scores, focusing on Physical Functioning (PF). Pearson's correlation coefficients assessed relationships between efficacy endpoints (oral ulcer count, oral ulcer pain, Behçet's Syndrome Activity Scale (BSAS), Behçet's Disease Current Activity Form (BDCAF)) and QoL endpoints for apremilast at Week 12.

Results: Apremilast (n=104) demonstrated significantly greater improvements versus placebo (n=103) in SF-36v2 PCS (3.1 vs 0.9), MCS (4.6 vs ─0.7) and PF (2.9 vs 0.14), respectively (all p<0.05). Mild correlations were observed in improvements of SF-36v2 measures (PCS, MCS, PF) with oral ulcer count (r=-0.11, PCS), and change in oral ulcer pain from baseline (r=-0.28, PCS; r=-0.10, PF) and BSAS (r=-0.38, PCS; r=-0.20, PF; r=-0.16, MCS). Correlations among BDCAF and SF-36v2 components and BDQoL were variable. BDQoL showed mild/moderate correlations with SF-36v2 components (r=-0.18, PCS; r=-0.13, PF; r=-0.45, MCS).

Conclusions: Apremilast was associated with significant improvements in QoL measures of SF-36v2 PCS, MCS and PF and BDQoL in patients with Behçet's syndrome. Correlations of improvement among QoL endpoints support the beneficial clinical effects of apremilast in Behçet's syndrome.

Trial registration number: NCT02307513.
Files in This Item:
T202205122.pdf Download
DOI
10.1136/rmdopen-2022-002235
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Do Young(김도영) ORCID logo https://orcid.org/0000-0002-0194-9854
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/191713
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links